News stories about Luminex (NASDAQ:LMNX) have trended somewhat positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Luminex earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media headlines about the medical instruments supplier an impact score of 44.9344439420741 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Luminex (NASDAQ:LMNX) opened at $20.64 on Friday. Luminex has a twelve month low of $17.68 and a twelve month high of $22.42. The company has a market cap of $916.77, a P/E ratio of 31.27, a price-to-earnings-growth ratio of 1.99 and a beta of 0.19.
Luminex (NASDAQ:LMNX) last announced its earnings results on Monday, October 30th. The medical instruments supplier reported $0.25 EPS for the quarter, beating the Zacks’ consensus estimate of $0.19 by $0.06. Luminex had a net margin of 9.52% and a return on equity of 6.01%. The business had revenue of $74.14 million during the quarter, compared to analysts’ expectations of $74.38 million. During the same period in the prior year, the company earned $0.21 earnings per share. The firm’s revenue was up 4.1% on a year-over-year basis. analysts predict that Luminex will post 0.49 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which was paid on Friday, January 12th. Shareholders of record on Friday, December 22nd were issued a dividend of $0.06 per share. The ex-dividend date of this dividend was Thursday, December 21st. This represents a $0.24 dividend on an annualized basis and a yield of 1.16%. Luminex’s dividend payout ratio is currently 36.36%.
Several research firms have recently weighed in on LMNX. BidaskClub raised shares of Luminex from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 10th. BTIG Research began coverage on shares of Luminex in a report on Friday, January 5th. They set a “buy” rating and a $24.00 price objective for the company. Jefferies Group reissued a “hold” rating and set a $21.00 price objective on shares of Luminex in a report on Friday, October 20th. Finally, TheStreet raised shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. One research analyst has rated the stock with a sell rating, four have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. Luminex currently has an average rating of “Hold” and an average target price of $21.50.
In other Luminex news, Director G Walter Loewenbaum II sold 50,000 shares of the company’s stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $21.79, for a total transaction of $1,089,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 131,698 shares of company stock valued at $2,761,201. 6.90% of the stock is owned by corporate insiders.
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.